Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
BioXcel Therapeutics Inc
BTAI
Healthcare
Biotechnology
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation...
associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:BTAI)
New Post
View:
Posts & Comments
Threaded Posts
(205)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Sep 19, 2024 7:32pm
BioXcel Therapeutics Announces Clinical Prioritization and U
Breaking News: $BTAI BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for AgitationRecently initiated SERENITY At-Home pivotal Phase 3 trial for
...more
(9)
•••
MikeTester
X
View Profile
View Bullboard History
Post by
MikeTester
on Aug 02, 2024 2:07pm
BioXcel Therapeutics, Inc. (NASDAQ:BTAI): Advancing Neurosci
https://beyondspx.com/2024/07/31/bioxcel-therapeutics-inc-nasdaqbtai-advancing-neuroscience-and-immuno-oncology-pipelines-driving-igalmi-commercialization/
(205)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 13, 2024 1:15pm
Why BioXcel Therapeutics Shares Are Rising Tuesday | Benzing
BREAKING NEWS: $BTAI Why BioXcel Therapeutics Shares Are Rising Tuesday | BenzingaBioXcel Therapeutics, Inc.@(NASDAQ:BTAI) shares are@jumping on Tuesday.The company announced that it has terminated
...more
(205)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 13, 2024 11:45am
BioXcel Therapeutics Announces Termination of Proposed Publi
BREAKING NEWS: $BTAI BioXcel Therapeutics Announces Termination of Proposed Public OfferingNEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a
...more
(205)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 09, 2024 9:15pm
BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating
BREAKING NEWS: $BTAI BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
...more
(205)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 06, 2024 4:15pm
BioXcel Therapeutics Announces Completion of Patient Enrollm
Breaking News: $BTAI BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with
...more
(0)
•••
JGrabar
X
View Profile
View Bullboard History
Post by
JGrabar
on Nov 30, 2023 1:36pm
$BTAI Shareholder Investigation
https://grabarlaw.com/the-latest/bioxcel-shareholder-investigation/ A recently filed securities fraud class action complaint alleges that BioXcel Therapeutics Inc. (NASDAQ: BTAI), via certain
...more
(66)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 25, 2023 3:38pm
BTAI.....ST Pumper says adding here at $2.90
LMFAO
(205)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jul 18, 2023 4:00pm
BTAI Investors Have Opportunity to Lead BioXcel Therapeutics
BREAKING NEWS: $BTAI BTAI Investors Have Opportunity to Lead BioXcel Therapeutics, Inc. Securities Fraud LawsuitBTAI Investors Have Opportunity to Lead BioXcel Therapeutics, Inc. Securities Fraud
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Learn About a Mining Portfolio of More Than 250 Projects and Royalties Across North America
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.
Nanalysis Announces Third Quarter 2024 Conference Call
GameSquare to Report Q3 2024 Financial Results on November 14, 2024
Options Trading for Retiring: Key Strategies in Balancing Retirement Income